GlassScriptPhysician profile
Chitra Venkatraman
NPI 1558354860
$2,784.59
in general payments reported to CMS, 2019-2025
37 companies · $362 in 2025
The $362 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $11.43 · 2021: $164 · 2022: $1,061 · 2023: $188 · 2024: $699 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,024 · Education: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,024.40 |
| Education | $225.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $268.79 | 2019-2024 | Darzalex |
| Pfizer INC. | $192.35 | 2021-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $173.79 | 2021-2023 | Imbruvica |
| Celgene Corporation | $165.43 | 2019-2024 | Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $162.15 | 2022 | |
| Daiichi Sankyo INC. | $153.09 | 2022-2024 | Enhertu |
| Gilead Sciences, INC. | $146.33 | 2021-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $113.08 | 2019-2025 | Keytruda Qlex, Keytruda, Lynparza |
| Abbott Laboratories | $112.01 | 2025 | Esprit |
| Tactile Systems Technology INC | $97.77 | 2019 | |
| Glaxosmithkline, LLC. | $95.00 | 2022-2024 | Zejula, Jemperli, Ojjaara |
| Beigene USA, INC. | $91.79 | 2022-2024 | Brukinsa |
| Astellas Pharma US INC | $85.47 | 2022-2025 | Padcev |
| Novartis Pharmaceuticals Corporation | $80.36 | 2022-2024 | |
| Array Biopharma INC | $73.51 | 2022-2025 | Braftovi, Lorbrena |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $73.47 | 2019-2024 | Phesgo |
| Astrazeneca Pharmaceuticals LP | $70.37 | 2019-2022 | |
| Rigel Pharmaceuticals, INC. | $57.06 | 2022 | |
| Amgen INC. | $54.76 | 2022 | |
| Abbvie INC. | $48.92 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $45.97 | 2021 | |
| Myriad Genetic Laboratories, INC. | $44.69 | 2022 | |
| Eisai INC. | $43.14 | 2019-2022 | |
| Organon LLC | $40.79 | 2022-2024 | |
| Seagen INC. | $39.31 | 2022 | |
| Pharmaessentia USA Corporation | $33.08 | 2024 | Besremi |
| Kite Pharma, INC. | $25.59 | 2025 | Yescarta |
| Genzyme Corporation | $24.35 | 2022 | |
| Stemline Therapeutics INC. | $23.83 | 2025 | Orserdu |
| Tersera Therapeutics LLC | $21.79 | 2022 | |
| Acrotech Biopharma INC. | $21.65 | 2024 | Beleodaq |
| Verastem, INC. | $19.62 | 2019 | |
| Global Blood Therapeutics, INC. | $18.75 | 2022 | |
| Incyte Corporation | $17.37 | 2019 | |
| Alnylam Pharmaceuticals INC. | $17.17 | 2024 | Givlaari |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2025 | Libtayo |
| Tempus Ai, INC | $14.97 | 2025 | Xt Cdx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chitra Venkatraman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.